Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Bought by Pinnacle Wealth Planning Services Inc.

Pinnacle Wealth Planning Services Inc. lifted its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 203.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 26,744 shares of the company's stock after purchasing an additional 17,930 shares during the quarter. Pinnacle Wealth Planning Services Inc.'s holdings in Dr. Reddy's Laboratories were worth $422,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of RDY. Crossmark Global Holdings Inc. grew its holdings in Dr. Reddy's Laboratories by 328.3% during the 4th quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company's stock valued at $201,000 after purchasing an additional 9,781 shares during the last quarter. Atomi Financial Group Inc. purchased a new position in shares of Dr. Reddy's Laboratories during the fourth quarter valued at approximately $162,000. SG Americas Securities LLC bought a new position in shares of Dr. Reddy's Laboratories during the fourth quarter valued at approximately $145,000. Drive Wealth Management LLC raised its holdings in shares of Dr. Reddy's Laboratories by 391.5% in the fourth quarter. Drive Wealth Management LLC now owns 13,451 shares of the company's stock worth $212,000 after buying an additional 10,714 shares during the period. Finally, Blue Trust Inc. lifted its stake in shares of Dr. Reddy's Laboratories by 46.3% during the 4th quarter. Blue Trust Inc. now owns 18,210 shares of the company's stock worth $288,000 after acquiring an additional 5,763 shares during the last quarter. Hedge funds and other institutional investors own 3.85% of the company's stock.

Dr. Reddy's Laboratories Trading Up 1.3%

RDY traded up $0.19 on Thursday, reaching $14.75. 1,473,285 shares of the company traded hands, compared to its average volume of 1,489,006. The company has a market cap of $12.31 billion, a P/E ratio of 23.48 and a beta of 0.33. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. Dr. Reddy's Laboratories Limited has a one year low of $12.26 and a one year high of $16.89. The firm has a fifty day simple moving average of $13.64 and a two-hundred day simple moving average of $14.01.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. The business had revenue of $996.17 million during the quarter, compared to analyst estimates of $83.70 billion. As a group, equities research analysts expect that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen raised Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.